Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interchangeable Biosimilars: FDA Clarifies US Reference Not Mandatory For Studies

Executive Summary

Draft guidance strongly recommends against it, but US FDA's Leah Christl says agency is willing to talk about using foreign-licensed comparators.

You may also be interested in...



Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching

Substituting a biosimilar for a reference product is a state issue and outside agency's purview, FDA says.

Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability

Industry calls for more education amid concerns that brand sales reps are encouraging providers to use only interchangeable products because they are better than biosimilars.

Humira Biosimilar Interchangeability: The Race Begins

Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel